Randall E. Woods
Director Ejecutivo en Tychan Pte Ltd. .
Perfil
Randall E.
Woods was the founder of Sequel Pharmaceuticals, Inc. founded in 2007, where he held the titles of President, Chief Executive Officer & Director.
Currently, he is the Chief Executive Officer & Director at Tychan Pte Ltd.
since 2021, Chairman at Sorbent Therapeutics, Inc. since 2012, and Director at Eden Woods Investments LLC.
Mr. Woods has an undergraduate degree from Ball State University (Indiana) in 1973 and an MBA degree from Western Michigan University.
Cargos activos de Randall E. Woods
| Empresas | Cargo | Inicio |
|---|---|---|
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Presidente | 19/04/2012 |
Eden Woods Investments LLC
 Eden Woods Investments LLC Financial ConglomeratesFinance Eden Woods Investments LLC provides investment services. The company was founded on May 5, 2011 and is headquartered in Rancho Santa Fe, CA. | Director/Miembro de la Junta | - |
Tychan Pte Ltd.
 Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Director Ejecutivo | 01/01/2021 |
Antiguos cargos conocidos de Randall E. Woods.
| Empresas | Cargo | Fin |
|---|---|---|
| ARENA PHARMACEUTICALS | Director/Miembro de la Junta | 12/06/2020 |
Sequel Pharmaceuticals, Inc.
 Sequel Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA. | Fundador | 01/09/2011 |
NovaCardia, Inc.
 NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Director Ejecutivo | 01/09/2007 |
| Corvas International, Inc. | Director Ejecutivo | 01/07/2003 |
| Boehringer Mannheim Pharmaceuticals Corp. | Presidente | 01/03/1996 |
Formación de Randall E. Woods.
| Ball State University (Indiana) | Undergraduate Degree |
| Western Michigan University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Empresas privadas | 10 |
|---|---|
| Corvas International, Inc. | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Sophiris Bio, Inc.
 Sophiris Bio, Inc. Pharmaceuticals: MajorHealth Technology Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. | Health Technology |
NovaCardia, Inc.
NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Health Technology |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Health Technology |
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
| Boehringer Mannheim Pharmaceuticals Corp. | |
Sequel Pharmaceuticals, Inc.
Sequel Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA. | Retail Trade |
Eden Woods Investments LLC
Eden Woods Investments LLC Financial ConglomeratesFinance Eden Woods Investments LLC provides investment services. The company was founded on May 5, 2011 and is headquartered in Rancho Santa Fe, CA. | Finance |
Tychan Pte Ltd.
Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Health Technology |
- Bolsa de valores
- Insiders
- Randall E. Woods
